Spartalizumab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | PD-1 (CD279) |
| Clinical data | |
| Other names | PDR001 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Spartalizumab (INN;[1] development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma.
This drug is being developed by Novartis. As of 2018[update], spartalizumab is undergoing Phase III trials.[2]
